Learn more about whether Inari Medical, Inc. or DENTSPLY SIRONA Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Stryker reported goodwill and other impairments of $818 million related to the spine business in the fourth quarter.
Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to ...
Learn more about whether Bausch + Lomb Corporation or Inari Medical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
We recently compiled a list of the 10 Hottest Smid-Cap Stocks So Far In 2025. In this article, we are going to take a look at where Inari Medical, Inc. (NASDAQ:NARI) stands against the other smid-cap ...
As the name suggests, smid-cap stocks have a valuation between $200 million and $20 billion. The definition is pretty ...
We recently compiled a list of the 10 Hottest Mid-Cap Stocks So Far in 2025. In this article, we are going to take a look at ...
Insights into the digital tools that can help improve patient engagement and advance understanding in deep vein thrombosis ...
Inari shareholders are getting a fair price relative ... risks and costs of thrombolytic therapy (drugs meant to break up clots) and a growing database on the safety and efficacy of mechanical ...
Inari (NASDAQ:NARI) had been working with advisers ... to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases. Overall, NARI ranks ...
based Stryker has offered $4.9 billion to buy Inari Medical Inc., a California company that specializes in equipment for venous thromboembolism (VTE) systems to treat blood clots such as pulmonary ...
The deal for Inari bolsters Stryker's efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases.